At Cellectar we believe that our targeted delivery platform has the potential to develop new and better treatments for patients and to prolong and improve their quality of life.

Our Company

We foster a culture of innovation, collaboration, and determination that begins with our leaders and permeates throughout the entire company. It drives all of our efforts and fuels our passion to make a significant and positive impact in the lives of patients, families and caregivers.

Targeted Delivery Platform

Our next generation delivery vehicle possesses the potential to deliver a broader array of warhead specifically to the tumor and generate better patient outcomes; greater efficacy and less side effects.


Targeted Therapies

Our lead product candidate, CLR 131, is a Phospholipid Drug Conjugate™ (PDC) providing targeted delivery of a cytotoxic (cell-killing) iodine 131 with our PLEs across a wide variety of hematologic and solid cancers. Our pipeline also includes a series of preclinical PDC programs delivering chemotherapeutic warheads with our PLEs.


Clinical Trials

CLR 131 is currently being evaluated in a Pivotal Trial for Waldenstrom’s macroglobulinemia as well as Phase 1 and Phase 2 clinical studies in other oncology indications.

Clinical Trials

Our Strategy

Our core strategy is to develop new targeted treatments for cancer patients suffering from rare/orphan designated cancers where there is high unmet medical need and limited treatment options.

Employing a collaborative outsourcing model to drug discovery and development

This allows us to efficiently and cost effectively design, research and advance drug candidates.

Iterative Screening Paradigm

Allows us to rapidly and systematically screen multiple generations of PDCs to produce the optimal drug candidates in the shortest time frame.

Strategic Drug Development

We focus our development efforts on market opportunities that can get our product candidates to patients as rapidly and as cost effectively as possible. These markets also offer us the greatest potential for success because they have limited competition and are easily scalable for a small company. At the same time, we are allowed to develop our product candidates through proof of concept studies in larger markets where these molecules could be attractive to larger commercialization partners.

Collaboration Strategy

We look to identify strategic collaboration(s) that can supplement internal resources, help us gain access to novel molecules or warheads for our PLEs, accelerate product candidate development in larger markets and broaden our product pipeline. We expect some of these collaborations will generate near-term capital and result in opportunities for Cellectar to further expand its portfolio.

Almost 100 Years of Combined Healthcare Leadership

Our executive team boasts extensive healthcare leadership experience within notable companies such as Novartis, Bristol Myers Squibb, Melinta Therapeutics and more.

Management Team Board of Directors